Resurrecting the House Call

New at-home strategies for hematologic conditions offer improved outcomes and patient satisfaction Physician home visits have become a thing of the past: Nearly a century ago, house calls made up 40 percent of U.S. doctors’...

Online Exclusives

Quality of Generic Drugs Manufactured Overseas Comes into Question

The passage of the Hatch-Waxman Act in 1984, which created a regulatory track for generic drugs, marked the beginning of the generic-drug boom in...

Who Foots the Surprise Bill?

As U.S. Senators prepare for a July vote on proposed legislation that would protect patients from surprise medical bills, three key players in the...

News

From the Blood Journals

Hematologic Malignancies Drive In-Hospital Death Rates

In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...
WIB_icon

Evaluating Thalidomide-Cyclophosphamide-Prednisone for Idiopathic Multicentric Castleman Disease

An oral combination of thalidomide, cyclophosphamide, and prednisone (TCP) induced durable tumor and symptomatic response rates in nearly half of patients with newly diagnosed...

Multimedia

Pulling Back the Curtain: Lukas Wartman, MD

In more from our interview with Lukas Wartman, MD, he discusses his decision to go into medicine and his life as a doctor and...

Pulling Back the Curtain: Dan Pollyea, MD, MS

In more from our interview with Dan Pollyea, MD, MS, he shares what he learned from growing up watching his father practice medicine and the simple...

Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism

Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...

Ravulizumab: A New Treatment Option for PNH?

Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

On Location

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS)...

Are CAR T-Cell Therapies Moving to Hodgkin Lymphoma?

Results from two studies presented at the 2019 Transplantation & Cellular Therapy Meetings suggest that...

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Post-transplant maintenance therapy with midostaurin was safe and reduced relapse risk in patients with FLT3-mutated...

Post-Transplant Ixazomib Maintenance Prolongs Survival in Newly Diagnosed Myeloma

For patients with newly diagnosed multiple myeloma (MM) who relapse following autologous hematopoietic cell transplantation...

Adoptive “Non-Engineered” T-Cell Therapy Shows Preliminary Efficacy in Lymphomas

Chimeric antigen receptor (CAR) T-cell therapies engineered to recognize and destroy CD19 antigens on the...

Beta-Thalassemia Gene Therapy Continues to Show Efficacy in Longer-Term Follow-up

Updated results from the phase I/II HGB-204 and HGB-207 trials indicated that several patients with...

Latest Headlines

Advertisement

ASH Directions

Seventh Edition of ASH-SAP Coming Soon, CDC Responds to ASH’s Concerns About Opioid Guidelines

CDC Clarifies Opioid Prescribing Guideline at Urging of Hematology and Oncology GroupsHematologists, especially sickle cell disease (SCD) specialists, are welcoming a recent clarification from...

ASH Expands Global Initiative, Awards Research Award to Minority Scholar

ASH Expands Global Initiative With Research Award for Hematologists Outside North America  The American Society of Hematology (ASH) Global Research Award was established in 2018...

Sign up for our
eNewsletter!

Remembering Arthur Rosenberg, Dorothy Tuan Lo, and more

Remembering Arthur Rosenberg (1935 – 2018) Arthur Rosenberg, MD, FRCPC, a former chief of hematology at the Jewish General Hospital (JGH) in Montreal, Quebec, passed...

Remembering Francesco Lo Coco, NYU Langone Health to Establish Center for Blood Cancers, and...

Remembering Francesco Lo Coco (1955 – 2019)  Francesco Lo Coco, MD, a renowned leukemia researcher and pioneer of targeted therapy, passed away on March 3,...

Boston Children’s Hospital Receives $1.5 million for SCD Research, Fred Hutch Names New Endowed...

Weill Cornell Researchers Awarded $9 Million for Lymphoma Research The National Cancer Institute (NCI) awarded a five-year, $9-million Program Project Grant (P01) to Weill Cornell...

Resurrecting the House Call

New at-home strategies for hematologic conditions offer improved outcomes and patient satisfaction Physician home visits have become a thing of the past: Nearly a century...

CMML: A Unique Overlap Syndrome Receiving Increased Attention

For many years, chronic myelomonocytic leukemia (CMML) has been treated as a form of myelodysplastic syndrome (MDS), despite its unique clinical and biological characteristics. “Everyone...

New Treatment Options Lead to New Questions in Acute Myeloid Leukemia

For the past 40 years, the standard remission induction treatment for patients with newly diagnosed acute myeloid leukemia (AML) who are candidates for intensive...